Abstract:BackgroundMirk/Dyrk1B contributes to G0 arrest by destabilization of cyclin D1 and stabilization of p27kip1 to maintain the viability of quiescent human cancer cells, and it could be negatively regulated by mitogenic-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling. This study was performed to investigate the effect of Mirk/Dyrk1B on cell cycle and survival of human cancer cells involving MAPK/ERK signaling.MethodsThe correlations between Mirk/Dyrk1B expression and active ERK1/2 detected by western blot in both ovarian cancer and non-small cell lung cancer (NSCLC) cells were analyzed by simple regression. Mirk/Dyrk1B unique phosphopeptides with sites associated with Mirk/Dyrk1B protein were isolated and quantitated by liquid chromatography coupled to tandem mass/mass spectrometry (LC-MS/MS) proteomics analysis. The human cancer cells were treated with small interfering RNAs (siRNAs) and/or U0126, an inhibitor of MEK for indicated duration, followed by investigating the alterations of cell cycle and apoptosis as well as related proteins examined by flow cytometry and Western blot, respectively.ResultsOur study demonstrated the widely expressed Mirk/Dyrk1B proteins in the human cancer cells were positively correlated with the levels of activated ERK1/2. Moreover, Mirk/Dyrk1B protein expressions consistent with the tyrosine autophosphorylated levels in the human cancer cells were increased by U0126 or growth factor-depleted culture. Conversely, knockdown of Mirk/Dyrk1B by siRNA led to up-regulated activation of c-Raf-MEK-ERK1/2 pathway and subsequent changes in cell cycle proteins (cyclin D1, p27kip1), accompanied by increased growth rate and cells from G0/G1 into S of cell cycle which could be blocked by U0126 in a dose-dependent manner, indicating Mirk/Dyrk1B may sequester MAPK/ERK pathway, and vice versa. Whereas, combined Mirk siRNA and U0126 induced cell apoptosis in the human cancer cells.ConclusionsThese data together show that Mirk/Dyrk1B mediates cell cycle and survival via interacting with MAPK/ERK signals and simultaneous inhibition of both pathways may be a novel therapeutic target for human cancer.

Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells

Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells

YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating C-Myc.

Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells

Proline-rich Tyrosine Kinase 2 and Its Phosphorylated Form Py881 Are Novel Prognostic Markers for Non-Small-cell Lung Cancer Progression and Patients’ Overall Survival

Oncogene DEK is Highly Expressed in Lung Cancerous Tissues and Positively Regulates Cell Proliferation As Well As Invasion.

High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial–mesenchymal Transition

RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition.

PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma

DYRK2 downregulation in colorectal cancer leads to epithelial–mesenchymal transition induction and chemoresistance

Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.

FYN Promotes Breast Cancer Progression Through Epithelial-Mesenchymal Transition.

TrkB is Highly Expressed in NSCLC and Mediates BDNF-induced the Activation of Pyk2 Signaling and the Invasion of A549 Cells

Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation

ERK1 indicates good prognosis and inhibits breast cancer progression by suppressing YAP1 signaling.

PBK promotes aggressive phenotypes of cervical cancer through ERK/c‐Myc signaling pathway

YB-1 is a Positive Regulator of KLF5 Transcription Factor in Basal-Like Breast Cancer

Ciliogenesis-associated Kinase 1 Promotes Breast Cancer Cell Proliferation and Chemoresistance Via Phosphorylating ERK1